Inclusion criteria were as follows ,  age ,  18 to 65 years ,  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 ,  primary tumors subfascially localized with diameter greater than or equal to 5 cm ,  high-grade spindle-cell or polymorphous sarcomas (fibrosarcoma ,  malignant fibrous histiocytoma ,  polymorphous liposarcoma ,  leiomyosarcoma ,  synovial sarcoma ,  malignant schwannoma ,  angiosarcoma ,  and polymorphous rhabdomyosarcoma) ,  local relapse of any size ,  no previous radio/chemotherapy ,  adequate bone marrow (WBC count of >= 4,000/fiL ,  platelets = 120.000/mL ,  and hemoglobin >= 10 g/dL) ,  renal (creatinine <= 1.3 mg/dL) ,  hepatic (SGOT <= 2.5 X normal value and bilirubin <= 1.2 mg/dL) ,  and pulmonary functions .
The preliminary data of previous studies were sometimes positive for DFS and OS , 15-19 but further analyses ,  made after an adequate follow-up time ,  indicated a disappearance of the positive effect of chemotherapy on 20,21 and ,  in some cases ,  worse results.22 However ,  the recently published meta-analysis , 7 involving 1,568 patients ,  showed a statistically significant benefit for treated patients of 6% ,  10% ,  and 10% for local ,  metastatic ,  and overall DFS ,  respectively ,  and a favorable (but not statistically significant) trend in OS (4%) ,  after a median of 9.4 years of follow-up .
